UCB (OTCMKTS:UCBJF) Stock Passes Below Fifty Day Moving Average – Time to Sell?

UCB SA (OTCMKTS:UCBJF)’s share price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $308.77 and traded as low as $304.29. UCB shares last traded at $304.29, with a volume of 155 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research started coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. Barclays reissued an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Stephens reaffirmed an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research note on Monday, December 8th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50 day moving average is $309.15 and its 200 day moving average is $282.85.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.